GHRS
GH Research·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Shooting Star
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GHRS
Gh Research Plc
A clinical stage biopharmaceutical company that develops novel therpies for the management of mental diseases
Joshua Dawson House, Dawson Street, Dublin 2, D02 RY95, Ireland
--
GH Research PLC was incorporated under the laws of Ireland on 29 March 2021. The company is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of mental and neurological diseases. The company's initial focus was to develop a new patented mebphenolone for the treatment of patients with treatment-resistant depression (TRD). The Company's product portfolio currently includes GH001, the Company's proprietary inhalable 5-MeO-DMT product candidate, delivered via vaporization equipment manufactured by third parties, and GH002, the Company's proprietary injectable 5-MeO-DMT product candidate. The company has completed a Phase 1 healthy volunteer clinical trial in which GH001 administered by inhalation was observed to be well tolerated at the study's single-dose level and individualized dosing regimen, with dose escalation in subjects within one day. GH001 is currently being studied in the Phase 2 portion of a Phase 1/2 clinical trial in patients with TRD.
Company Financials
EPS
GHRS has released its 2025 Q3 earnings. EPS was reported at -0.23, versus the expected -0.23, meeting expectations. The chart below visualizes how GHRS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
